SEC Form 4 · accession 0001127602-19-001770
CVS HEALTH Corp · CVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Larry J Merlo
Officer — President and CEO · Director
Period of report
Jan 8, 2019
Accepted (ET)
Jan 10, 2019 · 4:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000064803
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 8, 2019 | M | 166,368 | $45.07 | A | 496,577 | D | |
| Common StockF2 | Jan 8, 2019 | S | 166,368 | $69.04 | D | 330,209 | D | |
| Common Stock | holding | — | — | — | 378,463 | I | By Trust As Beneficiary | |
| Common Stock (restricted) | holding | — | — | — | 127,881 | D | ||
| ESOP Common Stock | holding | — | — | — | 6,972 | I | By ESOP | |
| Stock Unit | holding | — | — | — | 646,899 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF3 | $45.07 | Jan 8, 2019 | M | 166,368 | D | Apr 2, 2013 | Apr 2, 2019 | Common Stock | 166,368 | 166,368 | D |
| Phantom Stock CreditsF4,F5,F6 | $1.00 | holding | — | — | — | — | — | Common Stock | 5,143 | 5,143 | D |
| Stock OptionF7 | $54.53 | holding | — | — | — | Apr 1, 2014 | Apr 1, 2020 | Common Stock | 314,713 | 314,713 | D |
| Stock OptionF8 | $74.29 | holding | — | — | — | Apr 1, 2015 | Apr 1, 2021 | Common Stock | 335,697 | 335,697 | D |
| Stock OptionF9 | $102.26 | holding | — | — | — | Apr 1, 2016 | Apr 1, 2022 | Common Stock | 273,929 | 273,929 | D |
| Stock OptionF10 | $104.82 | holding | — | — | — | Apr 1, 2017 | Apr 1, 2023 | Common Stock | 286,787 | 286,787 | D |
| Stock OptionF11 | $78.05 | holding | — | — | — | Apr 3, 2018 | Apr 3, 2024 | Common Stock | 338,105 | 338,105 | D |
| Stock OptionF12 | $62.21 | holding | — | — | — | Apr 1, 2019 | Apr 1, 2025 | Common Stock | 394,091 | 394,091 | D |
Explanation of responses
- F1All sales were effected pursuant to a Rule 10b5-1 plan.
- F10Option became exercisable in four equal annual installments, commencing 4/1/2017.
- F11Option became exercisable in four equal annual installments, commencing 4/3/2018.
- F12Option becomes exercisable in four equal annual installments, commencing 4/1/2019.
- F2Represents weighted average sale price for this group of sales, which occurred on the same trading day. Multiple sales were executed, with sales prices ranging between $68.72 and $69.65 per share.
- F3Option became exercisable in four equal annual installments, commencing 4/2/2013.
- F4Each share credit is equivalent to one share; 1-for-1 conversion.
- F5Reflects year end company match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
- F6Reflects year end company match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
- F7Option became exercisable in four equal annual installments, commencing 4/1/2014.
- F8Option became exercisable in four equal annual installments, commencing 4/1/2015.
- F9Option became exercisable in four equal annual installments, commencing 4/1/2016.